Comparing Biologic Pathways and Screening for HS Comorbidities

In "Comparing Biologic Pathways and Screening for HS Comorbidities," the panel works through biologic sequencing before turning to the comorbidities that shadow this patient's disease.

Asked how they sequence biologic therapy, Dr. Cices explains that comorbid inflammatory bowel disease drives her toward TNF inhibitors first, since infliximab and adalimumab carry substantial off-label use in that setting. Absent contraindications, however, she now favors IL-17 inhibition first, citing strong efficacy with fewer adverse effects and noting the irony that originator TNF inhibitors have grown harder to get approved as biosimilars flood that market. Cynthia Trickett cites Italian data showing that a diagnostic delay beyond ten years cuts the odds of achieving fifty percent lesion clearance by week sixteen below fifty percent. The panel debates whether TNF-alpha and IL-17 inhibition sit on the same inflammatory pathway or represent genuinely separate targets, agreeing some patients need dual-pathway therapy since epigenetics can shift which cytokine dominates at different points in a patient's disease, with nodules driven more by one inflammatory cell type early and tunnels by another later.

The conversation shifts to comorbidities. Panelists screen for the follicular occlusion tetrad, PCOS, and inflammatory bowel disease, and one adds depression as an unlisted but near-universal fifth comorbidity, alongside sexual dysfunction that patients rarely raise unprompted. They describe leaning on psychiatry, gastroenterology, rheumatology, and pain management colleagues, while acknowledging psychiatric referral is often the hardest to arrange due to insurance limits. Pain management draws candid discussion, including occasional opioid use for severe perianal abscesses and patient use of medical cannabis; panelists note that smoked cannabis still generates pro-inflammatory combustion byproducts, so they steer patients toward tinctures or edibles instead, which may carry anti-inflammatory benefit without that downside.

In "HS Case Study: Setting Treatment Goals in Severe Disease," the panel introduces its third and final case: a 42-year-old man with 12 years of poorly controlled disease.